产品说明书

JQEZ5

Print
Chemical Structure| 1913252-04-6 同义名 : JQ-EZ-05
CAS号 : 1913252-04-6
货号 : A921258
分子式 : C30H38N8O2
纯度 : 98%
分子量 : 542.675
MDL号 : MFCD31619231
存储条件:

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 25 mg/mL(46.07 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 As a master regulator of chromatin function, the lysine methyltransferase EZH2 (enhancer of zeste homologue 2) orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers, such as non-small cell lung carcinoma (NSCLC). JQEZ5 is a novel and potent EZH2 inhibitor which shows antitumor efficacy. Human oncogene wild-type NSCLC cells H661 treated with increasing concentrations of JQEZ5 demonstrated acutely reduced levels of H3K27me3, which prompted silencing of tumor suppressors and developmental regulators and was associated with over-expression of EZH2. This assay supported the notion that JQEZ5 was effectively targeting EZH2 in human lung cancer cell lines. Tumor-bearing mice treated with JQEZ5 for three weeks (75 mg/kg intraperitoneal (IP) daily) exhibited rapid and pronounced tumor regression over the three week treatment course. Additionally, H3K27me3 levels were largely reduced with treatment further confirming the on-target effect of JQEZ5 in mice [1].
作用机制 D-pyridinone ring of JQEZ5 binds to Asn78 on EZH2, and that the pyrazolo-pyridine ring is deeply buried in the S-adenosyl methionine (SAM)-binding pocket of EZH2 .
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.84mL

0.37mL

0.18mL

9.21mL

1.84mL

0.92mL

18.43mL

3.69mL

1.84mL

参考文献

[1]Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, Herter-Sprie GS, Kikuchi E, Carretero J, Perou CM, Reibel JB, Paulk J, Bronson RT, Watanabe H, Brainson CF, Kim CF, Hammerman PS, Brown M, Cichowski K, Long H, Bradner JE, Wong KK. Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discov. 2016 Sep;6(9):1006-21. doi: 10.1158/2159-8290.CD-16-0164. Epub 2016 Jun 16. PMID: 27312177; PMCID: PMC5010480.